BioAffinity (BIAF) shares rose over 8% in pre-market trading after reporting a 146% year-over-year increase in Q1 CyPath Lung test sales. The AI-powered test detects lung cancer at Stage 1A. CEO Maria Zannes highlighted the test's ability to address critical diagnostic gaps and improve patient outcomes by reducing invasive procedures.